Following on from information provided to NICE by the company in October 2017 the appraisal of Anacetrapib for patients with hypercholesterolaemia and/or hyperlipidaemia; add on therapy adjunct to statin therapy [ID1165] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.